

Provider Bulletin

News and Information



May 15, 2025

Enhanced medical drug biosimilar step therapy criteria update

Effective July 1, 2025, UCare will update the biosimilar step therapy criteria within medical drug policies to require a trial of a preferred biosimilar product when all medical necessity criteria are met. This includes, but is not limited to, an allergic reaction to a specific inactive ingredient in the preferred biologic or use for a diagnosis not approved for the preferred biosimilar product. The facility's unwillingness to order or stock the preferred product(s) will not be considered. The updates will be implemented for members in all lines of business, Medical Assistance (Medicaid), UCare's Individual and Family Plans (IFP) and Medicare.

Policy

Provider will find this policy in [UCare's Medical Drug Policies](#) library on July 1, 2025.

Contact UCare's Provider Assistance Center at 612-676-3300 or 1-888-531-1493 toll-free, Monday through Friday, 8 am – 5 pm with questions.